Montmorency Cherry Juice and Uric Acid Metabolism

April 2, 2013 updated by: Glyn Howatson, Northumbria University

The Influence of Tart Montmorency Cherries on Indices of Uric Acid Metabolism

Cherries have been show to possess the ability to reduce uric acid concentrations and inflammation. Tart Montmorency cherries possess a higher concentration of the plant compounds than other cherries and hence makes the expectation possible that Montmorency cherries will lower uric acid and inflammation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Plasma and urinary uric acid concentration, plasma phytochemical content and inflammatory biomarkers will be measured in order to elucidate the effects of an acute dose of tart cherry juice on indices related to the condition of gout.

Participants will be required to attend the laboratory at a range of time points over two periods of 96 hours, separated by a 7 day washout period, to provide blood samples. In order to provide a baseline sample, participants will attend the laboratory in the morning following an overnight fast and voiding of any urine. Following this participants will be given 30mls (30 mls provides 323 mg/380 µmol of anthocyanins) of tart cherry juice or placebo, diluted with 60 mls of water to consume within 10 minutes. Participants will be required to consume identical dosages of the supplement immediately prior to evening meals and breakfasts (or same time each morning following blood sampling if non-breakfast eater) over the next 96 hours. Further blood and urine samples will be collected at 1, 2, 3, 5, 8, 24, 26, 48, 50, 72, 74 and 96 hours and will require participants to return to the laboratory at each of these time points. Following the first period of supplementation participants will complete a 7 day washout period in which they will not be required to attend the laboratory. Following the washout period they will repeat the supplementation period consuming the supplement they did not receive during the first period.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 8ST
        • Northumbria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • apparently healthy males/females between the ages of 18-40 years

Exclusion Criteria:

  • underlying clinical pathology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: low dose
Montmorency cherry concentrate, 30 mls
Dietary supplement: Montmorency cherry concentrate
Tart Montmorency cherry juice concentrate
Experimental: higher dose
Montmorency cherry concentrate, 60 mls
Dietary supplement: Montmorency cherry concentrate
Tart Montmorency cherry juice concentrate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in uric acid
Time Frame: 0, 1, 2, 3, 5, 8, 24, 26, 48 hours
measurement of changes in uric acid over a 48h period
0, 1, 2, 3, 5, 8, 24, 26, 48 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in C-reactive protein
Time Frame: 0,1,2,3,5,8,24,26,48 hours
measurement of changes in c-reative protein over a 48h period
0,1,2,3,5,8,24,26,48 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in anthocyanins, polyphenolics and creatinine
Time Frame: 0,1,2,3,5,8,24,26,48 hours
measurement of changes in anthocyanins, polyphenolics and creatinine over a 48h period
0,1,2,3,5,8,24,26,48 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Northumbria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

March 1, 2013

Study Registration Dates

First Submitted

March 29, 2013

First Submitted That Met QC Criteria

April 2, 2013

First Posted (Estimate)

April 5, 2013

Study Record Updates

Last Update Posted (Estimate)

April 5, 2013

Last Update Submitted That Met QC Criteria

April 2, 2013

Last Verified

April 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RE10-01-12554
  • 914 (Northumbria University)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Clinical Trials on Montmorency cherry concentrate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe